
Cyclacel Pharmaceuticals Investor Relations Material
Latest events

Q2 2024
Cyclacel Pharmaceuticals

Q2 2025
13 Aug, 2025

Q1 2025
15 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cyclacel Pharmaceuticals Inc
Access all reports
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company's research and development efforts target the regulation of the cell cycle, aiming to treat cancers and other serious diseases that result from abnormal cell division. Cyclacel's pipeline includes small-molecule drugs designed to inhibit specific enzymes and proteins involved in cancer cell growth and survival. The company's therapeutic candidates are being developed for a range of oncology applications, with the goal of addressing unmet medical needs in cancer treatment. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CYCC
Country
🇺🇸 United States